Clinical trials: Glioblastoma, WHO Grade IV
Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
RATIONALE: Genetically-modified neural stem cells (NSCs) that convert 5-fluorocytosine (5-FC) into the chemotherapy agent 5-FU (fluorouracil) at sites of tumor in the brain may be an effective treatment for glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma, Recurrent Grade IV Glioma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT01172964
- Testing
- flucytosine, polymerase chain reaction, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Targeted Pediatric High-Grade Glioma Therapy
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma
- Trial name
- NCT05839379
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 350 people
- Sponsor
- Nationwide Children's Hospital
Glioblastoma
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma.
- Trial name
- INTELLANCE-2 (NCT02343406)
- Testing
- Depatuxizumab mafodotin, Temozolomide, Lomustine
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 266 people
- Sponsor
- AbbVie
Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV
International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)
The HIT-HGG-2013 trial offers an innovative high-quality diagnostics and science program for children and adolescents >3 years, suffering from one of the following types of high grade gliomas: 1.
- Conditions
- Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV, Anaplastic Astrocytoma WHO Grade III, Diffuse Intrinsic Pontine Glioma
- Trial name
- HIT-HGG-2013 (NCT03243461)
- Testing
- Temozolomide + Valproic Acid
- Where
- 51 sites in Germany
- Volunteers
- 167 people
- Sponsor
- University of Göttingen
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in…
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma
- Trial name
- NCT05843253
- Testing
- Ribociclib, Everolimus, Temozolomide (TMZ)
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 120 people
- Sponsor
- Nationwide Children's Hospital
Recurrent High-grade Glioma, Grade III Astrocytoma
Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma
This is a Phase I study of ex vivo expanded CD34+ hematopoietic stem cells (exHSCs) plus nivolumab in pediatric patients with histologically confirmed diagnosis of a non-brainstem high-grade glioma (NB-HGG, WHO Grade III or IV…
- Conditions
- Recurrent High-grade Glioma, Grade III Astrocytoma, Oligodendroglioma, Oligoastrocytoma
- Trial name
- Peds CHAMP1ON (NCT07031765)
- Testing
- exHSC, Nivolumab, Resection or biopsy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Florida
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma
- Trial name
- NCT06333899
- Testing
- Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Nationwide Children's Hospital
High Grade Glioma, Astrocytoma
Study of Olutasidenib and Temozolomide in HGG
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation.
- Conditions
- High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
- Trial name
- NCT06161974
- Testing
- Olutasidenib + TMZ
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 60 people
- Sponsor
- Rigel Pharmaceuticals
Glioblastoma Multiforme, Glioblastoma
Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas)
Purposes: The purpose of this phase-II clinical trial is to determine whether or not ADCTA-G, a biologic "vaccine" preparation of patient's own dendritic cell (DC) for glioblastoma multiforme (GBM) treatment, is safe and…
- Trial name
- NCT02772094
- Testing
- Single arm, open-label
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- China Medical University Hospital
Glioblastoma, IDH1 Gene Mutation
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back.
- Conditions
- Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma
- Trial name
- PNOC017 (NCT03749187)
- Testing
- PARP Inhibitor BGB-290, Temozolomide (TMZ)
- Where
- 11 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of California, San Francisco
Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma
- Trial name
- NCT03919071
- Testing
- Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture
- Where
- 131 sites in United States, Puerto Rico
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, High-Grade Glioma (WHO III-IV)
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
This is an open label, intra-patient dose escalation, to evaluate ADI-PEG 20, in combination with Temozolomide (TMZ) and radiation therapy (RT) in children, adolescents and young adult patients with newly diagnosed high grade…
- Conditions
- Glioblastoma, High-Grade Glioma (WHO III-IV), High-grade Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Trial name
- NCT07389278
- Testing
- ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT)
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Sabine Mueller, MD, PhD
Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma)
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of avutometinib and defactinib and to determine the preliminary antitumour activity of avutometinib and defactinib administered at the recommended…
- Conditions
- Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas
- Trial name
- 5G-RUBY (NCT06630260)
- Testing
- Avutometinib, Defactinib, Temozolomide
- Where
- 3 sites in United Kingdom
- Volunteers
- 182 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Adult Glioblastoma, High Grade Glioma
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in (Stratum 1) adult patients with newly diagnosed GBM (MGMT low level or…
- Conditions
- Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
- Trial name
- PNOC020 (NCT04573140)
- Testing
- Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Florida
Glioblastoma, Malignant Glioma
Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
The purpose of this study is to determine the feasibility and safety of administering CMV RNA-pulsed dendritic cells (DCs), also known as CMV-DCs, to children and young adults up to 35 years old with nWHO Grade IV glioma…
- Conditions
- Glioblastoma, Malignant Glioma, Medulloblastoma Recurrent, Pediatric Glioblastoma Multiforme
- Trial name
- ATTAC-P (NCT03615404)
- Testing
- CMV-DCs with GM-CSF, Td (tetanus toxoid)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Gary Archer Ph.D.
Glioblastoma Multiforme (WHO Grade IV), Anaplastic Astrocytoma (WHO Grade III)
Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy
Cure rates for patients with high grade glioma remain disappointing, in part because tumor cells are often resistant to chemotherapy, and because using higher doses of chemotherapy causes damage to normal blood cells.
- Trial name
- NCT00272870
- Testing
- 06Benzylguanine, MGMT P140K, Meltenyi CliniMacs
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma)
5G-EMERALD: Amivantamab in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of amivantamab and to determine the preliminary antitumour activity of amivantamab administered at the recommended Phase 2 dose (RP2D).
- Conditions
- Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Glioblastoma Multiforme (GBM)
- Trial name
- 5G-EMERALD (NCT06632236)
- Testing
- Amivantamab
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Institute of Cancer Research, United Kingdom